Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified MINE regimen based on liposomal mitoxantrone for relapsed/refractory primary CNS lymphoma
ChiCTR2200061723Phase 2Not yet recruiting
- Sponsor
- The Second Hospital of Nanjing
- Start
- Oct 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone hydrochloride liposome, ifosfamide, mesna and etoposide in primary central nervous system lymphoma (PCNSL), sponsored by The Second Hospital of Nanjing. Primary endpoint: Best overall response rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposomeifosfamidemesnaetoposide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2200061723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061723.